Atrial flutter gives a sawtooth appearance on the ECG, with repeated P wave occurring at around 300 per minute, with a narrow complex tachycardia.
Seen best in lead V1
Although people with atrial flutter often have no symptoms, symptoms can include:
palpitations
shortness of breath
fatigue
syncope
chest pain
Treatment for atrial flutter:
beta-blocker or calcium channel blocker
an intravenous beta-blocker or verapamil hydrochloride is preferred for rapid control.
If a patient with atrial flutter is haemodynamically unstable then direct current cardioversion is used
Catheter ablation can stop the re-entry path in atrial flutter. Patients should be anticoagulated for at least 3 weeks
patients with atrial flutter should be offered anticoagulation based on the CHA2DS2-VASc score.
Paroxysmal SVT often terminates spontaneously or with:
valsalva manoeuvre
putting face in ice cold water
carotid sinus massage
If manoeuvres for SVT do not work or patient has severe symptoms, administer IV adenosine. If this does not work it suggests the arrhythmia is of atrial origin such as AF
Haemodynamically unstable patients with SVT need direct current cardio version
Patients with recurrent SVT can be treated with catheter ablation. SVT can be prevented with beta blockers and calcium channel blockers
Ventricular tachycardia is commonly due to scarring post MI
Pulseless VT is a shockable cardiac arrest rhythm
most patients with VT receive a pacemaker. It can be managed with beta blockers and/or amiodarone
Ventricular fibrillation causes no coordinated electrical activity on an ECG. There is a chaotic fibrillating baseline. This is incompatible with life and leads to cardiac arrest
Patients in VF require defibrillation and amiodarone. They can have an internal defibrillator implanted.
Inappropriate sinus tachycardia is where there is no underlying pathology causing the tachycardia. Eliminate triggers. Can be treated with ivabridine, beta blockers and calcium channel blockers
Patients with bradycardia that are unstable and at risk of asystole should receive IV atropine and inotropes (adrenaline)
Atrial Fibrillation is a type of SVT that causes the atria to fibrillate. This causes an irregularly irregular pulse. Blood can stagnate in the atria leading to an increased risk of clot formation.
Atrial Fibrillation causes irregularly irregular ventricular contraction. This leads to impaired filling during diasystole - therefore patients are at risk of heart failure
Patients with atrial fibrillation are often asymptomatic, but can present with:
Palpitations
SOB
Pre-syncope / syncope
Symptoms of associated conditions such as stroke and sepsis
Common causes of AF can be remembered as SMITH:
S - Sepsis
M - mitral valve pathology
I - ischaemic heart disease
T - thyrotoxicosis
H - Hypertension
Other causes include PE, alcohol and caffeine
Types of atrial fibrillation:
Paroxysmal - brief event that may go away on its own. Often tachy-brady syndrome
Persistent - lasts more than a week, could still terminate with no treatment
Long term persistent - more than a year
Permanent - does not terminate even with medication due to remodelling and damage to the circuit
Atrial fibrillation on an ECG will show:
Absent P waves
Irregular and narrow QRS complexes
24hr tape may be needed to diagnose paroxysmal AF
Bloods for AF: U&Es, TFTs and cardiac enzymes
Consider an echo for patients with AF to look for:
Left atrial enlargement and hypertrophy
Mitral valve disease
Poor LV function - heart failure
All patients with AF will receive rate control and anticoagulation. Rhythm control is indicated when:
Reversible cause
new onset <48 hours
Heart failure caused by AF
Persistent symptoms
First line rate control in AF is beta blockers
Target is to keep heart rate below 100 so time is extended for ventricles to fill with blood
Rate limiting calcium channel blockers can also be used but they are contraindicated in heart failure
Digoxin if persistent symptoms but monitor for toxicity
Amiodarone is an anti-arrhythmic that can be used in heart failure patients for long term control of atrial fibrillation
Rhythm control can be done pharmacologically or electrically
Pharmacological cardioversion - flecainide and propafenone
Electrical cardioversion - immediate if patient unstable or delay and anti-coagulate patient for at least 3 weeks
First line anticoagulation for AF is DOACs such as rivaroxaban and apixaban
Give warfarin if DOACs contraindicated
If patient acutely unwell give heparin
DOACs shouldn't be given to patients with mechanical valves due to increased risk of thromboembolism and bleeding
CHA2DS2-VASc score is used to calculate stroke risk in patients with AF and decide if they need anti-coagulation:
0 - no anticoagulation
1 - consider anticoagulation in men
2 - offer anticoagulation
ORBIT score is used to calculate the risk of major bleed in patients on anticoagulation with AF
Torsades de pointes:
Consequence of prolonged QT interval
Will terminate spontaneously and revert to sinus rhythm or progress to VT
Causes of prolonged QT:
Long QT syndrome (inherited)
Medications - macrolide antibiotics (clarithromycin) and amiodarone
Electrolyte imbalances - hypokalaemia, hypomagnesaemia and hypocalcaemia
Medications that prolong QT:
Antipsychotics
Citalopram
flecainide
Sotalol
Amiodarone
Macrolide antibiotics - Azithromycin, clarithromycin and erythromycin
Acute management of torsades de pointes:
Correct underlying cause
Magnesium infusion
Defibrillation if ventricular tachycardia occurs
Wolff-parkinson-white syndrome:
Preexcitation syndrome - double excitation of ventricles
Congenital accessory pathway - Bundle of Kent
Short PR interval and delta wave (early slurred upstroke in the QRS)
Main concern is development of AF
During symptomatic episode - same treatment as SVT
Amiodarone
Catheter ablation
Avoid AV node blockers
AV node blocking drugs:
Adenosine
Calcium channel blockers
Beta blockers
Digoxin
Macrolide antibiotics e.g. erythromycin can cause QT prolongation - Torsades de pointes